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S U M M A R Y
Objectives: To characterize the seroepidemiological features of Pneumocystis jirovecii infection in healthy
Chilean children using overlapping fragments (A, B, C) of the P. jiroveciimajor surface glycoprotein (Msg).
Methods: Serum antibodies toMsgA,MsgB, andMsgCweremeasured every 2months by enzyme-linked
immunosorbent assay (ELISA) in 45 Chilean infants from about age 2 months to 2 years.
Results: Peak antibody levels (usually reached at age 6 months) and the force (or rate) of infection were
somewhat greater for MsgC than for MsgA. Signiﬁcant seasonal variation in antibody levels was only
found with MsgA. Respiratory infections occurred in most children, but nasopharyngeal aspirates were
of limited value in detecting the organism. In contrast, serological responses commonly occurred, and
higher levels only to MsgC were signiﬁcantly related to the number of infections.
Conclusions: Serological responses to recombinant Msg fragments provide new insights into the
epidemiological and clinical features of P. jirovecii infection of early childhood. MsgA, the amino
terminus fragment, is more sensitive in detecting seasonal inﬂuences on antibody levels, whereas MsgC
is better able to detect changes in antibody levels in response to clinical infection.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Pneumocystis jirovecii remains an important cause of serious
pneumonia (‘Pneumocystis pneumonia’ or PcP) in HIV-infected
patients and other immunocompromised hosts.1 Serological
studies have shown that primary P. jirovecii infection (as deﬁned
by the development of antibody responses to Pc antigens) is
acquired in early childhood; so by 2–3 years of age, 70–90% of
healthy children have serum antibodies to the organism.2–5 It is
thought that this infection is mild or asymptomatic.4,6–8 One study
found that the presence of P. jirovecii DNA detected by the
polymerase chain reaction (PCR) was more commonly associated
with upper respiratory tract infection (URI) symptoms than lower
respiratory tract infection (LRI) symptoms.9
These serological studiesmainly used antigens that consisted of
crude extracts obtained from Pneumocystis-infected human or
rodent lung.10 Attention was focused on the time when antibodies
were ﬁrst detected and cumulative seropositivity over time. Little* Corresponding author. Tel.: +1 513 475 6328; fax: +1 513 475 6415.
E-mail address: peter.walzer@va.gov (P.D. Walzer).
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doi:10.1016/j.ijid.2010.07.003was known about the speciﬁc antigens that were recognized by
serum antibodies, the rate or force of infection, or whether
antibody levels varied over time.10
The development of recombinant P. jirovecii antigens has begun a
newera in serology,with attention focusedmainly on twomoieties:
the major surface glycoprotein (Msg) and kexin (Kex1).11,12 We
selectedMsg asour target antigenbecause it elicits a strong immune
response, contains protective epitopes, and plays amajor role in the
interaction of Pneumocystis with its mammalian host.1,13–15 We
developed three overlapping recombinant fragments (Msg A, B, and
C) that span the entire length of a single Msg isoform: MsgA, the
amino terminus, which is quite variable; MsgB, the mid portion;
MsgC, the carboxyl terminus,which is themost conserved fragment.
We analyzed reactivitywith serumantibodies in prevalence studies
and in HIV patients and other adult populations, and found that
MsgCwas best able to distinguish (1) HIV patients hospitalizedwith
PcP from patients with pneumonia due to other causes, (2) HIV
patientswhohadpreviousPcP frompatientswhonever hadPcP, and
(3) healthcare workers who had clinical contact with patients from
workers who did not.16–18We then developed variants (Msg C3, C8,
and C9) of the parent MsgC (C1) in order to better delineate the
reactivity of this antigen.19–21ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Percentiles (%) of the distributions of maximum peak antibody levels to MsgA and
MsgC and the age (months) when these levels were reached
No. of
peaks
Median
(25th, 75th percentiles)
Age (25th, 75th
percentiles)
MsgA 37 21.2 (11.0, 34.8) 12 (8, 17)
MsgC 42 48.5 (12.3, 110.7) 10 (8, 14)
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pathogens, such as the variant surface antigen (VSA) of Plasmodi-
um and the variant surface glycoprotein (VSG) of Trypano-
soma,22,23 Msg is encoded by multiple genes and is thus capable
of antigenic variation.24 Serological surveys of young children, who
experience most of the malaria fatalities, and of adults in an
endemic area provide information about the host immune
response to VSA, which is important for vaccine develop-
ment.25–27 Analysis of serum antibody responses of populations
in different geographic areas, climates, and seasons can enhance
understanding of the host and environmental effects on the
expression of VSA epitopes and their recognition by host
antibodies.28–30 Our studies so far have revealed geographic, but
not seasonal differences in the serological antibody responses to
Msg in adults.21
One of us (SLV) previously followed healthy infants during the
ﬁrst 2 years of life with regular visits and with nasopharyngeal
aspirates (NPAs) taken when there were respiratory symptoms.4 P.
jirovecii DNAwas detected in NPAs in 32% of these episodes, and at
a signiﬁcantly younger age than the NPAs that were negative for P.
jirovecii. Yet, detection of P. jirovecii did not identify a speciﬁc
pattern of symptoms. Serum antibodies to Pneumocystis murina
extracted from themousewith PcP, developed in 53% of the infants
at 8 months of age and in 85% of the infants by 20 months of age;
seroconversion occurred in the presence of respiratory symptoms
in 79% of the subjects. Thus, P. jirovecii or an immune response to
the organism could be frequently detected in healthy infants with
mild respiratory disease.
Little is known about the serological responses of infants and
young children to recombinant P. jirovecii antigens. In the present
study, we examined the sequential serum antibody responses to
Msg A, B, and C over a 2-year period in 45 infants from this
pediatric cohort. We wanted to compare the serological responses
to these antigens for their value in determining the force or rate of
infection; in looking for seasonal differences in antibody levels;
and in examining the host immune response to respiratory
infections.
2. Materials and methods
2.1. Patient population
In 1997, a total of 107 healthy infants were enrolled by 1month
of age in a 2-year prospective cohort study in Santiago, Chile.4
Follow-up occurred monthly at a well-baby clinic and serum
specimens were obtained every 2 months. Parents were asked to
report infections via the telephone or to bring the child to the
clinic. NPAs were obtained for P. jirovecii ampliﬁcation when a
respiratory tract infection was diagnosed, especially when cough
was reported. An infection was diagnosed as a URI if a cold
(rhinitis), nasopharyngitis, or pharyngitis were present. An LRI
consisted of bronchitis, bronchiolitis, or pneumonia. Other
manifestations such as tonsillitis, tonsillopharyngitis, or otitis
media were considered separate disorders. Serum specimens and
NPAs (which were mixed with saline) that were obtained were
stored at 70 8C. Chest radiographs were obtained when clinically
indicated. An informed consent form for study participation was
signed by both parents and approval for the studywas given by the
University of Chile Ethics Commission.
The 45 subjects in the present report were chosen because they
hadmany sequential serum specimens taken, reliable clinical data,
and exhibited a broad range of antibody responses to P. murina
extracted-puriﬁed antigen in the previous study. Serum samples
from the previous studywere available from 2 to 24months of age.
However, for the analysis of antibody peaks, rate or force of
infection, seasonal variation, and episodes of respiratory infection,only serum specimens obtained at or after 6 months of age were
used in order to control for maternal antibodies.
2.2. DNA ampliﬁcation
NPAs were examined for P. jirovecii by nested-DNA ampliﬁ-
cation of the large subunit mitochondrial ribosomal RNA gene of
P. jirovecii.4 NPA samples were digested with proteinase K
(20 mg/ml) at 60 8C in the presence of 10 mM ethylenediami-
netetraacetic acid (EDTA) and 0.5% sodium dodecyl sulfate
(SDS). Total DNA was puriﬁed and concentrated with use of the
Pharma-Gen ‘clean up’ system (Pharma-Gen) and recovered in a
volume of 50 ml. Five microliters of this DNA preparation were
used for DNA ampliﬁcation with P. jirovecii oligonucleotide
primers pAZ102-E (50-GATGGCTG-TAGG-30) and pAZ102-H (50-
GTGTACGTTGC-AAAGTACTC-30), which are internal to the ﬁrst
set of primers and speciﬁc for P. jirovecii, in a second round of
PCR take 1 ml from the ﬁrst-round PCR product . Ampliﬁed P.
jirovecii had a predicted length of 267 bp. Negative controls with
no added template DNA were included after each sample to
monitor for cross-contamination.
2.3. ELISA
Serum antibody levels to the recombinant Msg fragments were
analyzed in a blinded manner by an ELISA.16,17 We later made
slight modiﬁcations to the ELISA.19–21 Analysis of the same
specimens by both methods showed good correlation of the
results. The small amounts of serum in the specimens available to
us precluded repeating the analysis of the specimens in this study
by the new method. For similar reasons, we were only able to
measure IgG antibodies in this study.
All serum specimens and the standard reference serum were
diluted 1/100 and tested in duplicate wells of a 96-well plate
against the following antigens: MsgA, MsgB, and MsgC; Escherichia
coli extract expressing the pET vector without insert (vector
control); phosphate buffered saline (PBS) without antigen (nega-
tive control); and tetanus toxoid (TT) (positive control). The plates
were washed, followed by the addition of horseradish peroxidase
(HRP)-labeled goat anti-human IgG; the plates were washed again
and tetramethylbenzidine (TMB) substrate was added. The
reaction was stopped by the addition of 0.18 M H2SO4 and the
plates were read at a wavelength of 450 nm. The reference serum
specimen was obtained from a single individual with known
reactivity to Msg. This serum was run each day as an additional
control. HRP-labeled S-protein was used as a positive control and
to correct for antigen loading. The antibody level or reactivity of
each serum specimen to Msg was expressed as the ratio of
reactivity: (mean OD Msgtest serum  the mean OD PBStest serum)/
(mean OD pETtest serum mean OD PBStest serum).
2.4. Statistics
Antibody levels to Msg A, B, and C (C1) across time were
evaluated for each child. The median age at ﬁrst visit and median
duration of follow-up were calculated. Analysis of variance
(ANOVA) was performed to determine the differences in serum
Table 2
Percentiles (%) of the distributions of peak antibody levels to MsgA and MsgC by season; median peaks (25th, 75th percentiles)
Spring (Sept–Nov) Summer (Dec–Feb) Fall (Mar–May) Winter (Jun–Aug)
MsgAa 33.2 (12.0, 68.5); n=14 19.3 (13.1, 27.6); n=8 10.9 (3.9, 15.7); n=10 22.9 (10.4, 77.8); n=11
MsgC 28.3 (5.4, 139.4); n=13 53.7 (10.0, 84.9); n=10 46.8 (25.3, 80.0); n=6 52.3 (27.3, 110.7); n=13
n is the number of peaks.
a Seasonal median estimates were signiﬁcantly different (p=0.03 by Chi-square test) among the seasons.
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number of respiratory infections. Seasonwas deﬁned according to
the climate in Chile as follows: summer (December–February),
fall (March–May), winter (June–August), and spring (September–
November). The number of respiratory infectionswas categorized
as 0 (none), <3 (1–2 illnesses), and 3 illnesses. The maximum
(peak) antibody level to each antigen was obtained for each child.
The median and 25th and 75th percentiles of the set of all peak
valueswere calculated to describe the distributionof these values.
Similar percentiles of the distribution of ages when antibody
levels peaked were calculated. The average age when P. jirovecii
infection occurred was deﬁned serologically as the median age at
which the maximum of peak antibody levels occurred. The force
(rate or incidence) of infection was deﬁned as 1/median age of
infection. The relationship between peak antibody levels and age
at time of peak was graphically assessed to provide visual
summaries of trends over time. SAS forWindows, version 9.1 (SAS
Institute, Cary, NC, USA)was used for all the analyses and the level
of statistical signiﬁcancewas based on 5% level (two-sided) unless
stated otherwise.
3. Results
3.1. General demographic and serological ﬁndings
Themedian age atﬁrst visitwas2months, the visitswere about 2
months apart, and themedian follow-up timewas 19months. There
were 37 and 42 infants included in the analysis of MsgA and MsgC
distributions, respectively (Table 1). Although we had initially
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Figure 1. MsgC and MsgA antibody levels by age. The vertical lines show the
magnitude of the peaks. Note that the antibody peaks to MsgC are generally higher
and have a shorter interval between them than the peaks to MsgA.planned to examine serum specimens for all 45 subjects, we found
that there were missing specimens or specimens with insufﬁcient
amounts of serum for analysis. Since antibody levels to MsgB were
very low and showed few sequential changes, they were excluded
from the analyses. The median peak of antibody level to MsgC was
48.5vs.21.2 toMsgA.Asdeﬁnedbypeakantibody levels, themedian
age when primary P. jirovecii infection occurred was 10 months for
MsgC vs. 12 months for MsgA. The force of infection measured by
antibodies toMsgCwas10%permonthcomparedwith8%permonth
for antibodies to MsgA. Thus, MsgC tended to elicit higher antibody
levels and greater force of infection than MsgA, but the differences
were not statistically signiﬁcant.
3.2. Seasonal changes in antibody levels
The overall patterns of serological responses to MsgA andMsgC
were quite different (Table 2). The lowest level of antibodies to
MsgA was found in the fall (10.9), whereas the highest level was in
the spring (33.2). Levels in the summer were in between. The
seasonal differences in antibody levels to MsgA were signiﬁcant
(p = 0.03). In contrast to MsgA, high antibody levels to MsgC
ranging from 46.8 to 53.7 were found in summer, fall and winter;
the lowest antibody level was found in spring (28.3). However,
these results were not statistically signiﬁcant.
3.3. Antibody reactivity over the 2-year period
Most children had at least one major peak in their antibody
levels to MsgA or MsgC, some had several peaks, while others had
little or no peaks. The aggregate data also suggested that there
were distinct antibody peaks in the antibody levels that tended to
be grouped around speciﬁc ages rather than being uniformly
distributed (Figure 1). Antibody peaks to MsgC were usually
higher and had a shorter median interval between them (3.2
months) than the peaks to MsgA (3.7 months).
3.4. Antibody reactivity in individual subjects
Examples of the sequential antibody changes in individual
children exhibited considerable variation in the responses to MsgC
and MsgA (Figures 2 and 3). The most common pattern was one or
more antibody peaks to MsgC after clearance of the maternal
antibodies, which usually occurred at 6 months or the third clinic
visit. Changes in antibody responses to respiratory infection were
easy to ﬁnd. Yet, since these episodes occurred in the presence or
absence of detectable P. jiroveciiDNA on the NPAs, and detection of
P. jirovecii by PCR is highly dependent on the amount of sample
(DNA content) analyzed,31 it was difﬁcult to correlate these speciﬁc
antibody changes with nested PCR results.
3.5. Relationship of antibody levels to number of infections
In order to determine if there was an association between
antibody levels to MsgC or MsgA and the number of respiratory
infections developed by the children, we compared the geometric
mean (95% conﬁdence interval) of antibody levels of all visits for all
subjects with the same number of respiratory infections (Table 3).
K. Djawe et al. / International Journal of Infectious Diseases 14 (2010) e1060–e1066 e1063The data showed that therewas a progressive rise inmean antibody
levels to MsgC with increasing number of respiratory infections;
children experiencing three or more episodes had signiﬁcantly
higher antibody levels to MsgC than children who had experienced
no episodes or one to two episodes. By contrast, no such difference
was seen in the antibody levels to MsgA. We also examined these
antibody levels without controlling for maternal antibodies, and
again signiﬁcantly higher antibody levelswere found in the children
with three or more respiratory infections (data not shown).
In addition, we attempted by several different approaches to
correlate antibody levels to MsgC or MsgA with the speciﬁc types
of respiratory infection (URI or LRI), but the results were
inconclusive (data not shown).
4. Discussion
The present report is the ﬁrst seroepidemiological study of P.
jirovecii infection in children using recombinant antigen prepara-
tions. As in our previous studies of adults in the USA,16–19 the
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Figure 2. Examples showing the changes in antibody levels toMsgC over time in four chil
DNA, and Pc indicates NPA negative for P. jirovecii DNA. The vertical arrows show the v
visit 4 (8months of age), followed by a smaller peak at clinic visit 7. The ﬁrst respiratory i
that visit was negative for Pneumocystis (Pc). Subsequent episodes of illness occurred
Antibody levels toMsgC did not change after the ﬁrst illness, increased after the second il
peak at clinic visit 5 and the second peak at clinic visit 8. Illness occurred between visits
MsgC increased after both illnesses. Child 6 developed the ﬁrst and only MsgC antibody p
and between visits 5 and 6 (NPA Pc). There was no change in antibody levels after the
displayed the ﬁrst antibody peak at visit 6 and second peak at visit 8. Illness occurred at vi
Pc). Serum antibodies to MsgC rose after the ﬁrst three illness episodes and fell afterconsistently higher antibody levels elicited byMsgC suggest that it
is the predominant antigen recognized by serum antibodies in
Chilean infants and young children. MsgC also tended to elicit
higher and more rapid antibody peaks than MsgA, as illustrated in
the force of infection, which is an epidemiological tool that has
been helpful in studying the dynamics of infection, both in
populations and in models of infection.32–34
Previous reports have noted geographic differences in the
occurrence and P. jirovecii colonization in HIV patients.35,36 One
characteristic of multi-gene antigens used in serological surveys is
geographic variation in the antibody responses. Our serological
study of HIV subjects enrolled in theMulticenter AIDS Cohort Study
(MACS), which compared the reactivity of the four recombinant
MsgC fragments, demonstrated signiﬁcant differences in the
antibody levels to these MsgC fragments among the cities
(Baltimore, Pittsburgh, Chicago, and Los Angeles) where the study
was conducted.21 We also found that MsgC8 was the predominant
Msg fragment recognized in Seville, Spain, and that MsgA was the
major fragment recognized in Cameroon.20,37Child 14
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dren. Pc+ indicates nasopharyngeal aspirate (NPA) positive for Pneumocystis jirovecii
isits when the NPAs were obtained. Child 26 developed the ﬁrst major peak at clinic
llness that requiredmedical attention occurred between clinic visits 1 and 2; NPA at
between clinic visits 3 and 4 and at clinic visit 5; in both cases, the NPA was Pc+.
lness, and declined after the third illness. Child 14 developed the ﬁrst MsgC antibody
2 and 3 (NPA Pc+), and between visits 7 and 8 (NPA Pc). Serum antibody levels to
eak at visit 5. Illness occurred between visits 2 and 3 (NPA Pc+), at visit 4 (NPA Pc),
ﬁrst illness, a rise after the second illness, and a fall after the third illness. Child 45
sit 4 (NPA Pc), visit 5 (NPA Pc), visit 6 (NPA Pc), and between visits 6 and 7 (NPA
the fourth illness.
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Figure 3. Examples showing the changes in antibody levels toMsgA over time in four children. Pc+ indicates nasopharyngeal aspirate (NPA) positive for Pneumocystis jirovecii
DNA, and Pc indicates NPA negative for P. jiroveciiDNA. The vertical arrows show the visits when the NPAswere obtained. Child 12 exhibited the ﬁrst and only antibody peak
toMsgA at visit 4. Illness occurred at visit 2 (NPA Pc), between visits 2 and 3 (NPA Pc), at visit 3 (NPA Pc+), and at visit 9 (NPA Pc). Serum antibodies toMsgA rose after the
illness at visit 3. Child 39 developed the ﬁrst antibody peak at visit 3 and subsequent peaks at visit 6 and visit 8. Respiratory illness occurred at visit 1 (NPA Pc+), between visits
2 and 3 (NPA Pc), and at visit 6 (NPA Pc). Serum antibody levels rose after the ﬁrst illness, fell after the second illness, and rose again after visit 7 though therewas no illness
reported. Child 68 exhibited the ﬁrst and only MsgA antibody peak at visit 3. Illness occurred at visit 2 (NPA Pc) and between visits 4 and 5 (NPA Pc). The only serum
antibody rise occurred after the ﬁrst illness. Child 8 demonstrated no antibody peak to MsgA. Illness occurred between visits 2 and 3 (NPA Pc).
K. Djawe et al. / International Journal of Infectious Diseases 14 (2010) e1060–e10661064The impact of climate on the occurrence of Pneumocystis
infection in humans as well as in animals has been a subject of
considerable investigation.38–43 A complex and sometimes con-
tradictory relationship has been found: some studies have shown
an increased occurrence associated with warmer temperatures,
whereas other studies have found an increased association withTable 3
Serum antibody levels to MsgA andMsgC in the children by the number of episodes
of respiratory infection detected during the study
No. of serum specimens Mean ratio (percentiles 25–75)
MsgC MsgA
0 38 3.74 (2.18–6.40) 3.92 (2.41–6.38)
<3 147 5.59 (4.25–7.35) 3.21 (2.56–4.03)
3 125 12.44 (9.46–16.35)a 4.49 (3.59–5.61)
a Children who had three or more clinical diagnoses had signiﬁcantly higher
mean MsgC levels compared to those who had no diagnosis and those who had one
or two episodes (p<0.05 by ANOVA).colder temperatures or no seasonal association at all. Our study of
MACS subjects extended this debate to serological responses, but
found no seasonal differences in serological responses to the MsgC
fragments.21
The present report also found no signiﬁcant seasonal differences
in antibody responses to MsgC in young Chilean children; however,
the reportdid reveal adifferentpatternof reactivity toMsgAthatwas
associated with signiﬁcant differences among the seasons. The
reasons for these ﬁndings are not clear. Perhaps host recognition of
MsgA, which is the most exposed part of Msg, is more easily
inﬂuenced by changes in the environment (e.g., temperature,
humidity) than recognition of MsgC. In addition, the exposures of
the young children in this study differed from exposures in adults in
that many of these exposures were the children’s initial encounter
with the organism. These ﬁndings support our previous data, which
suggest that theMsg fragments are recognized independently by the
host.19–21 The results also emphasize the need for further
investigation of the effects of environmental factors on host
responses to P. jirovecii.
K. Djawe et al. / International Journal of Infectious Diseases 14 (2010) e1060–e1066 e1065While previous reports have focused on the time at which
children ﬁrst develop serum antibodies to P. jirovecii,4–6 the
present study examined the sequential changes in antibody levels
during the ﬁrst 2 years of life. Most subjects developed at least one
major peak to MsgC and/or MsgA, but there was considerable
variation in the individual responses. Perhaps the tendency for the
peaks to be grouped or clustered around speciﬁc ages was related
to maturational changes in the immune response or to age-related
environmental exposures. Although one study of P. jirovecii
colonization in families did not ﬁnd clustering,44 clustering of
serological responses in other infectious diseases has been
observed.28–30,45,46
Respiratory infections occurred in most of the children at some
point during the study, and were accompanied by antibody
responses to MsgC and/or MsgA. The children who had more
infections had signiﬁcantly higher mean antibody levels to MsgC
(but not toMsgA) than individuals who had fewer infections. These
data suggest thatMsgC antibody levels are amore sensitivemarker
of more frequent or more intense clinical exposure to P. jirovecii.
The results are also consistent with our previous reports of the
value of MsgC in discriminating present from past infection or
active disease from colonization.16,17,21
While the data in this report extend the results of the previous
study of these children,4 both studies have limitations. The
serological analysis was performed from an epidemiological point
of view and the small quantities of serum prevented analysis of IgM
antibodies; thus, the results should not be extrapolated to the
diagnosis of P. jirovecii infection. NPAs to detect P. jiroveciiwere only
performed when respiratory symptoms were present; testing for
other pathogens by culture, PCR, or serology was not performed.
Without this information, caution must be used in interpreting the
results. In addition, recent data show compartmentalization of P.
jirovecii colonization in the upper respiratory tract and that the yield
of non-invasive respiratory sampling increases if more than one
niche is sampled.31
In summary, this study shows that recombinant Msg fragments
are sensitive new tools that can provide new information about the
epidemiological and clinical features of P. jirovecii infection in early
childhood. MsgA, the amino terminus fragment, appears to be
more sensitive in detecting seasonal inﬂuences on immune
responses, while MsgC, the carboxyl terminus fragment, is more
effective in detecting changes in antibody levels in response to
clinical infection.
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